BiopharmaGLPG

Galapagos

Galapagos is a biotechnology company with a heritage in immunology and kinase biology, advancing the selective TYK2 inhibitor GLPG3667 across autoimmune diseases including dermatomyositis and systemic lupus erythematosus.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

Galapagos forecasting benchmarks

2 benchmarks

ResolvedPhase 3-enabling

GALARISSO & GALACELA: GLPG3667 (TYK2 inhibitor) in dermatomyositis and SLE

GLPG3667 · Dermatomyositis

Clinical Trials

ResolvedPhase 3-enabling

GALACELA (GLPG3667) Phase 3-enabling study in SLE

GLPG3667 · Systemic lupus erythematosus

Dec 18, 2025Clinical Trials

Pipeline on the platform

GLPG3667· Oral selective TYK2 inhibitor

Therapeutic areas

Dermatomyositis· DM Systemic lupus erythematosus· SLE

About Galapagos

What is Galapagos developing?

Which Galapagos trials can I forecast?

We track 2 Galapagos trial readouts as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes

BiopharmaGLPG

Galapagos

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

Galapagos forecasting benchmarks

2 benchmarks

ResolvedPhase 3-enabling

GALARISSO & GALACELA: GLPG3667 (TYK2 inhibitor) in dermatomyositis and SLE

GLPG3667 · Dermatomyositis

Clinical Trials

ResolvedPhase 3-enabling

GALACELA (GLPG3667) Phase 3-enabling study in SLE

GLPG3667 · Systemic lupus erythematosus

Dec 18, 2025Clinical Trials

Pipeline on the platform

GLPG3667· Oral selective TYK2 inhibitor

Therapeutic areas

Dermatomyositis· DM Systemic lupus erythematosus· SLE

About Galapagos

What is Galapagos developing?

Which Galapagos trials can I forecast?

We track 2 Galapagos trial readouts as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes